Sort
50,496 grants matching “lung cancer”
Validation of a microRNA panel to pre-symptomatically predict the risk of radiation-induced fibrosis
$533,384Claude J. Rogers · Chromologic, Llc · U01 · FY2025 · AI
Improving Radiologist Detection of Lung Nodules with CAD
$533,378Stanford University · R01 · FY2005 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
$533,358Anton Wellstein · Georgetown University · R01 · FY2021 · CA
Project 1 - Ethnic Differences in Smoking-Related Biomarkers and Risk of Lung Cancer
$533,347Sungshim Lani Park · University Of Minnesota · P01 · FY2016 · CA
TARGETING ADVANCED LUNG CANCER USING LETHAL HYPERACTIVATION OF THE UNFOLDED PROTEIN RESPONSE TO INDUCE TUMOR CELL DEATH AND IMMUNE CELL ACTIVATION
$533,347University Of Illinois · · FY2022 · Defense Health Agency
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
$533,344Anton Wellstein · Georgetown University · R01 · FY2020 · CA
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes
$533,326David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2022 · CA
Prospective Study of Human Oral Microbiome and Pancreatic Cancer Risk
$533,275Jiyoung Ahn · New York University School Of Medicine · R01 · FY2016 · CA
Optimizing Lung Cancer Treatment in HIV Infected Persons
$533,267Keith Magnus Sigel · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · CA
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss
$533,267Tal Teitz · Scintillon Institute For Photobiology · R01 · FY2025 · DC
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss
$533,267Tal Teitz · Scintillon Institute For Photobiology · R01 · FY2024 · DC
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment
$533,224Aaron N Hata · Massachusetts General Hospital · R01 · FY2021 · CA
Clinical Protocol and Data Management/Clinical Trials Office (Core 016)
$533,223Adam M Brufsky · University Of Pittsburgh At Pittsburgh · P30 · FY2015 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
$533,211Anton Wellstein · Georgetown University · R01 · FY2018 · CA
Brief Behavioral Intervention for Dyspnea in Patients with Advanced Lung Cancer
$533,179Joseph Andrew Greer · Massachusetts General Hospital · R01 · FY2017 · NR
Clinically-Relevant Regulatory Networks in the Lung Tumor Microenvironment
$533,147Sylvia Katina Plevritis · Stanford University · U01 · FY2014 · CA
Molecular mechanisms of SCLC initiation and detection in mice and humans
$533,142Mark A Krasnow · Stanford University · U01 · FY2022 · CA
Cancer Risks among Textile Workers in China
$533,108Harvey Checkoway · University Of Washington · R01 · FY2008 · CA
Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening
$533,083Vadim Backman · Northwestern University · R01 · FY2013 · CA
Genomic and functional approaches to characterize Chr1q gains in cancer
$533,035Jason Sheltzer · Yale University · R01 · FY2023 · CA
Studies of amplification in rhabdomyosarcoma
$532,984Frederic Barr · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Tissue Resident memory T cell responses to cancer
$532,934Mary J Turk · Dartmouth College · R01 · FY2021 · CA
Tissue Resident memory T cell responses to cancer
$532,934Mary J Turk · Dartmouth College · R01 · FY2020 · CA
Stanford Project 2
$532,885Calvin J Kuo · University Of California, San Francisco · U54 · FY2020 · CA
TARGETING LUNG CANCER WITH A DEFECT IN PP2A-B55 ALPHA
$532,875Ohio State University, The · · FY2020 · Defense Health Agency